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Abstract
The emerging technology of microarray analysis allows the establishment of molecular portraits of prostate cancer and the
discovery of novel genes involved in the carcinogenesis process. Many novel genes have already been identiﬁed using this
technique, and functional analyses of these genes are currently being tested. The combination of microarray analysis with other
recently developed high-throughput techniques, such as proteomics, tissue arrays, and gene promoter-methylation, especially
using tissue microdissection methods, will provide us with more comprehensive insights into how prostate cancer develops and
responds to gene-targeted therapies. Animal models of prostate cancer are being characterized by high throughput techniques to
better deﬁne the similarities and differences between those models and the human disease, and to determine whether particular
models may be useful for speciﬁc targeted therapies in pre-clinical studies. Although proﬁling of mRNA expression provides
important information of gene expression, the development of proteomic technologies will allow for an even more precise global
insight into cellular signaling and structural alterations during prostate carcinogenesis. Not only will the “omic” revolution
change basic science, but it will lead to a new era of molecular medicine.
Published by Elsevier B.V.
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1. Overview
Prostate cancer (PrCa) is a highly prevalent disease
and a leading cause of cancer deaths in men in the
Western world [1]. The incidence of prostate cancer
appears to be increasing, probably due to increased
patient screening using the prostate speciﬁc antigen
(PSA) serum assay, and clinical examinations. The
incidence of latent prostate cancer is similar in dif-
ferent regions throughout the world and between dif-
ferent racial groups, but this is not true for clinically
manifest prostate cancer [1]. Asians have the lowest
incidence of PrCa, whereas Western countries (espe-
cially the African-American population in the USA)
have the highest rates. Therefore, the progression from
latent to clinical cancer is a critical transition point in
the development of the disease. Understanding what
factors promote or inhibit this transition is crucial to
identifying who is at high risk of developing progres-
sive disease.
Diet is thought to be an important factor related to
prostate cancer development. Fat and red meat con-
sumptionhavebeenlinkedtoincreasedprostatecancer
incidence, whereas vegetarian diets and vitamin E-rich
diets seem to be protective [1]. More recent epidemi-
ological studies suggest that selenium may reduce the
risk of developing prostate cancer [2]. Understanding
the underlying molecular mechanisms leading to the
initiation and promotion of malignant and metastatic
prostate cancer remains a great challenge to identify
targets to prevent or control this disease.
Prostate intraepithelial neoplasia (PIN) is consid-
ered to be the precursor lesion of invasive prostate car-
cinoma[3].PINischaracterizedbyproliferationofthe
luminal epithelium within the acini and ducts. Prolif-
erating cells show nuclear pleomorphism and increase
in nucleolar size. PIN lesions are frequently seen in
prostates of men in the third decade of life and it
is thought that these lesions may slowly progress to
malignant PrCa over decades. PIN is present in more
than 85% of cases of PrCa [3]. Deﬁning molecular
mechanisms that trigger the progression of these early
lesions leading to PrCa is a key issue for developing
preventive therapies.
2. Molecular markers for prostate cancer
Prostatecancerinitiationandprogressionisamulti-
step process that includes chromosomal and gene
expressionalterationsleadingtocellproliferation,inhi-
bition of apoptosis, invasion, angiogenesis and metas-
tasis. Detailed reviews on the molecular biology of
prostate cancer have been previously published [4].
Some of the key molecular changes associated with
PrCa are discussed below. Such changes have been
identiﬁed in hormone signaling pathways, oncogenes,
suppressor genes, growth factor and growth factor
receptor genes, adhesion molecules and angiogenic
regulators.
The androgen receptor (AR) is a key molecule in
PrCa. Androgens, whose effect is mediated by AR, areA. Calvo et al. / Mutation Research xxx (2005) xxx–xxx 3
requiredforthedevelopmentofthenormalprostateand
PrCa [1]. Initially, anti-androgen therapy is effective in
70–80% of the patients. However, tumors usually re-
emerge and are refractory to hormone treatments [1].
This escape is thought to be due to alterations in AR
function, often by gene ampliﬁcation or mutations in
theARgene.Androgenindependenttumorsareusually
very aggressive and highly metastatic. Thus, nuclear
AR staining is four-fold less detectable in metastases
thaninprimarytumors[5].Therearenumerousstudies
on mutations of the AR gene, which happen in more
than 40% of primary tumors (often in the ligand bind-
ing domain). Ampliﬁcation of the AR gene has been
described in more than 30% of the tumors prior to
androgen therapy. AR ampliﬁcation may favor tumor
cell growth in the presence of low serum levels despite
anti-androgen therapy [6].
Oncogenes such as ras, myc and c-erb-B have been
implicated in PrCa, but they do not seem to be fre-
quently altered. Molecular analysis has shown that
mutations in ras, commonly found in some types of
tumors, are not very frequent in PrCa in Western coun-
tries. H-ras mutations are found in 5% of PrCa in
the USA [7]. K-ras mutations are more frequent in
Japanese males (25%) [8]. The expression of the anti-
apoptoticproteinBcl-2isnormallyalteredinPrCas[9].
This protein is usually undetectable in most hormone-
dependenttumorsbutitishighlyexpressedinhormone
refractory cancers. Bcl-2 appears to be associated with
thetransitiontohormoneindependencefromandrogen
dependence [10].
Tumor suppressor genes such as Rb have been
showntoplayaroleinprostatecarcinogenesis,andthe
alteration of both alleles of Rb leads to uncontrolled
proliferation. DU145 cells (which produce a truncated
form of Rb protein) transfected with functional Rb
leads to loss of tumorigenicity [11]. The tumor sup-
pressorgenep53ismutatedin10–20%ofpatientswith
PrCa. This frequency is low, compared to other types
oftumors.Severalgroupshavefoundhigherp53muta-
tions in PrCa bone metastasis [4]. NKx3.1 homeobox
gene is essential for normal prostate morphogenesis
and function, and its inactivations leads to epithelial
hyperplasia [4].
Thealterationintheexpressionofsomegrowthfac-
tors (GF) has been linked to PrCa. Examples of such
GF are TGF-, TGF-, IGF-I, and FGF [4]. TGF-
 is structurally similar to EGF and has a mitogenic
effect on normal epithelial and prostate cancer cells.
IncreasedexpressionofFGF-2,FGF-5,andFGF-3has
been described in PrCa [12]. FGFs are broad spec-
trum mitogens and can induce angiogenesis. The IGF
system includes a family of proteins and receptors
involved in prostate cell growth. IGF-I and IGF-II are
tumorigenic factors of prostate cancer. The IGF bind-
ing protein-2 (IGFBP-2) modulates IGF-II action in
malignant progression. Higher levels of IGFBP-2 are
related to aggressive clinical behavior after hormonal
therapy [13].
Aberrationsintheexpressionofadhesionmolecules
have been described as well. E-cadherin, which
belongs to the family of calcium-dependent adhe-
sion molecules, is frequently down-regulated during
prostatecarcinogenesis[14].-Catenin,aproteinasso-
ciatedwithinvasionandmetastasisisalteredinprostate
tumors [15]. Unlike colon cancer, where alteration of
-catenin is a frequent early event, it seems that muta-
tions of this gene in PrCa occur focally and are related
to late tumorigenesis [15].
Angiogenicfactorsandproteasesthataltertheextra-
cellular components of the prostate have been shown
to play an important role in tumor vascularization,
extravasation, invasion and metastasis. The expression
of the vascular endothelial growth factor (VEGF) and
its receptors is increased in the neoplastic prostate
compared to the normal prostate [16]. The matrix met-
alloproteinases (MMPs) include gelatinases and col-
lagenases that can regulate the extracellular matrix
(ECM). The PC-3 variant PC-3ML, that metastasizes
to the bone, expresses a higher amount of MMP-2
than its precursor cell [17]. MMP-7 (matrilysin) is
another important protease related to PrCa. MMP-
7 exhibits high proteolytic activity against collagen
IV, a major component of bone marrow stroma and
other basement membranes and has been found up-
regulatedinmetastaticprostatecancer[18].Theuroki-
nase plasminogen activator (uPA) is a serine protease-
type enzyme that releases plasmin. The up-regulation
of uPA is linked to the acquisition of the invasive phe-
notype [19].
In spite of all these data, our current knowledge on
markersforPrCaisinsufﬁcienttoexplainthecomplex-
ity of this disease and for the development of effective
therapies. Microarray analysis is expected to launch a
comprehensive proﬁle of genes involved in the differ-
ent steps of prostate carcinogenesis that can be used4 A. Calvo et al. / Mutation Research xxx (2005) xxx–xxx
as novel targets for therapy. This approach provides an
important component of biology analysis for prostate
cancer.
3. Genomic approaches
Anexplosioningenomicinformationandtechnolo-
gies are providing incredible opportunities to study
prostate cancer on an enormous scale. We begin to
understand that cancer is not simply the result of a few
aberrant genes, but results from a complex reorganiza-
tion or multiple genetic pathways and networks which
collectively provide the cancer cell with immortality
and, all too often, invincibility. The global molecu-
lar signatures of prostate cancer has recently begun to
be explored and deﬁned. Sequence databases coupled
with the tools of comparative genomic hybridization,
SAGE analyses, the Cancer Genome Anatomy Project
andmicroarraytechnologiesareleadingtotheidentiﬁ-
cationofgenesdifferentiallyregulatedbetweennormal
prostate epithelium, benign prostate hyperplasia, PIN
and prostate carcinoma.
The Cancer Genome Anatomy Project (CGAP)
created by the National Cancer Institute (NCI) is
an initiative whose goal is to achieve a comprehen-
sive molecular characterization of cancerous tissues
compared to their normal counterparts. The infor-
mation provided by CGAP is publicly available at
http://www.cgap.nci.nih.gov. This comprehensive site
providesawealthofinformationbaseduponthegener-
ation of cDNA libraries from tumor and normal tissues
as well as useful tools for data analysis. This informa-
tion has been extremely useful for identifying novel
targets for several types of cancers and was success-
fully used to identify novel genes expressed in prostate
cancer [20].
Microarrays contain thousands of gene sequences
(expressed sequence tags, or ESTs) from both known
anduncharacterizedgenes.ThehybridizationofcDNA
probes generated from tumor and a reference sample
(often normal tissues) onto the microarray provides
the means to monitor differences in gene expression
of thousands of genes in a single experiment and pro-
vides the information to identify “tumor ﬁngerprints”
[21]. Another important technique used to verify gene
expression and to localize the particular cell of origin
is the use of tissue microarrays. Analogous conceptu-
ally to cDNAs tissue arrays are composed of hundreds
of individual tissue samples placed on a single slide
which provides a means to evaluate the expression of
potential biomarkers by immunohistochemistry or in
situ hybridization. Tissue microarrays are being used
to validate expression patterns of genes newly identi-
ﬁed by microarray analysis. The development of these
new tools initiate a new era for the discovery of genes
involved in prostate cancer. This will hopefully lead
to the development of more accurate and effective tar-
getsfortherapy,theestablishmentofgeneticproﬁlesof
different patients or types of tumors, the evaluation of
therapeutic responses to drugs, and the determination
of new parameters to predict progression and survival.
However, many difﬁculties and challenges remain to
be overcome. The huge amount of data produced by
different array platforms has to be compared and ana-
lyzed in a meaningful way and translated into novel
and veriﬁable therapeutic applications.
This review is focused on recent advances in under-
standing prostate cancer through the use of microarray
technology.Techniquesforhigh-throughputevaluation
of gene expression in prostate cancer will be con-
sidered. Recent advances in the application of gene
expression proﬁling to both human PrCa and rodent
PrCa models will also be discussed.
4. Gene expression proﬁlingusingmicroarray
technology
4.1. Microarray platforms
Thetechnologyofhigh-throughputgeneexpression
analysis is rapidly developing. The most commonly
used platforms are the following: (a) high-density
oligonucleotide arrays; (b) cDNA glass-based arrays
using ﬂuorescence-labeled probes; and (c) cDNA
membrane-based arrays using radioactively-labeled
probes. Although we summarize brieﬂy the principles
of these technologies, these platforms are reviewed
more extensively elsewhere [22–24].
High-density oligonucleotide arrays consist of a
large number of gene-speciﬁc oligonucleotides of a
predeterminedsequence,synthesizedinsituorpresyn-
thesized and robotically spotted on a glass or sili-
con wafer support. Affymetrix oligonucleotide arrays
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widely used. These arrays use 25 base pair oligonu-
cleotides that are chemically synthesized onto a sili-
con surface using photolithographic technology [25].
Sample labeling and hybridization protocols use the
same basic system: Total RNA samples or poly A+
RNAarereversetranscribedintocDNAusinganoligo-
dT primer, which has the T7 polymerase promoter
sequence at the 5  end. Then, second strand cDNA
(ds-DNA) is synthesized and used as a template for
in vitro transcription using the T7 RNA polymerase,
thus generating cRNA in the presence of biotinylated
rNTPs. Each labeled cRNA from each sample is indi-
vidually hybridized onto the oligo-chip, and the sig-
nal is detected by the biotin-streptavidin-ﬂuorochrome
method. These ampliﬁcation protocols allow array
analysis on small samples, such as early tumor lesions
and biopsies, or samples of pure cell types obtained by
lasercapturemicrodissection(LCM).Oligonucleotide-
basedarrayshavenumerousadvantages.Theycancon-
tain a large number of probes (up to 500,000, approx-
imately), provide a strong inter-array reproducibil-
ity, and have a consistent amount of DNA per spot.
Oligonucleotidesaresingle-strandedsequencesanddo
notrequireadenaturationstep,thusavoidingadecrease
in hybridization efﬁciency due to the renaturation of
nucleicacids.cDNAglass-basedmicroarraysaremade
usingpuriﬁedcDNAs(generatedaseitherpuriﬁedPCR
products from cDNA clones, or from bacterial extrac-
tion) that are robotically spotted onto a chemically
treated glass slide (usually poly-l-lysine coated slides)
to produce an array with up to about 30,000 features.
The spotted cDNA is linked to the slide surface by
UV light or by heating using an oven. RNA extracted
from a sample of interest (tumor sample, treated cell
line, etc.) and RNA from the reference sample (nor-
maltissue,untreatedcellline)aredifferentiallylabeled
in separate reverse transcription reactions using two
different ﬂuorescent dye-conjugated d-UTP (usually
Cy3-andCy5-dUTP).ThelabeledcDNAsaremixedin
equal quantities, puriﬁed and competitively hybridized
onto the same arrays. cDNA microarrays are not fully
quantitative,providingrelativelevelsofmRNAspecies
or fold-changes in the transcript levels for each gene.
Detailed protocols for cDNA microarray analysis can
be found at: http://nciarray.nci.nih.gov/reference.
cDNA membrane-based arrays consist of probes
robotically spotted on a membrane-based matrix (usu-
ally made of Nylon), and are also called macroar-
rays. The extracted RNA is reverse transcribed incor-
porating a radioactive isotope such as 32P (although
non-radioactivechemiluminiscentmethodscanalsobe
used). After labeling and cDNA puriﬁcation, either
control or experimental samples are hybridized onto
individual arrays. Signal intensities are captured by
a Phosphoimager or X-ray ﬁlm, for each individual
sample applied to each membrane. The signal inten-
sities for the experimental samples are compared with
those of the reference samples, thus obtaining the rel-
ative expression level for each feature. Disadvantages
of this type of array compared to glass-based microar-
rays include the fact that the number of features is
usually much lower, the results are not as robust as
glass-basedarrays,andspecialprecautionsarerequired
when working with radioactivity. Despite these incon-
veniences, this method is easy to use, and does not
require expensive equipment.
4.2. Data analysis and data mining
Successfulmicroarraystudiesrequirecarefulexper-
imentaldesign.Importantissues,suchasthenumberof
samples and array replicates, experimental conditions,
and analytic strategies have to be addressed before
performing a particular study. Detailed considerations
related to study design have been reviewed by Simon
et al. [26].
Frequently used gene expression analysis tools are
able to identify sets of genes that have similar expres-
sionpatternsacrossseveralconditions(thusgenerating
genesassociatedwithcancerprogression,metastasisor
response to treatments), or group samples together that
share similar gene expression proﬁles across subsets
of genes (i.e. tumor classiﬁcation that can be used in
diagnosisandprognosis).Groupingofmicroarraydata
initially navigates in these two dimensions (genes and
conditions).Oncesubsetsofgenesassociatedwithcon-
ditionsofinterestaredeﬁned,moreprecisedatamining
can be performed.
Microarray data analysis is still an active ﬁeld of
research and no consensus has yet been reached on the
methodologiestobeemployed.Thisisamulti-steppro-
cedure that offers multiple options. Oligoarrays from
some vendors come with proprietary software pack-
ages that cover some or all steps of the analysis. In
this review, analysis of cDNA microarrays using dou-
ble ﬂuorescent probe labeling will be considered. The6 A. Calvo et al. / Mutation Research xxx (2005) xxx–xxx
ﬁrst step of the analysis is called “data normalization”.
Signal intensities from the scanned image (Cy3 and
Cy5)arebackground-subtracted.Thelog(base2)ofthe
ratio Cy5/Cy3 (log2(Cy5/Cy3)) is the most common
variable transformation used to report gene expression
data. Transformation into logarithms allows for much
easier manipulations of values, especially when ratios
become very small. In addition, logarithm transforma-
tionreducesvariabilityforhighﬂuorescentsignals,and
lower normalization may be used especially to correct
for heterogeneity of variance for low intensity val-
ues [27]. The log2(Cy5/Cy3) transformation has been
recentlychallengedbecauseitmaydistortthedata:Cy3
must be a non-zero value in order to calculate a ratio,
and Cy5 must be a non-zero value in order to calculate
logarithms. Also the coefﬁcient of variation (standard
deviation/mean) is much higher in log scale for low
intensities. To correct for unequal labeling between
Cy5 and Cy3, subtraction of the median (across the
array) of log2(Cy5/Cy3) is performed. However, this
procedure does not prevent nor solve artifacts due to
the ﬂuorescent dye choice for labeling and researchers
should always include “reverse labeling” of the same
“RNA sample” (Cy5 for reference RNA, and Cy3 for
condition) in their experimental design.
The second step of the analysis is typically an
exploratory visualization of the data where differ-
ent unsupervised methods can be used (unsuper-
vised meaning that the algorithm needs no a priori
assumption on class repartition). Hierarchical clus-
tering and trees, K-means clustering, self-organizing
maps(SOM),andprincipalcomponentanalysis(PCA)
or multidimensional scaling (MDS) can be used
depending on the type of experiment [24,28]. Several
optionsareavailableforhierarchicalclustering.(a)For
the metrics (measure of distance), the 2 main options
availableare1-Pearson’scorrelationandEuclideandis-
tance. The 1-Pearson’s correlation metrics should be
usedwhentrendsingeneexpressionarepursued,rather
thanabsolutedistance.Euclideandistanceistobeused
when absolute distance is more appropriate (i.e. time
point experiment or drug dosage series) [24]. (b) For
clustering (a method that includes several options for
linkage,suchassingle,average,orcomplete),theaver-
age linkage is used for most analyses. PCA or MDS
are used to visualize groups of conditions rather than
genes,becausethereareusuallymuchfewerconditions
thangenesintheanalysis,anditwouldbeveryconfus-
ing to represent several thousand of genes on a scatter
plot.
The third step is to ﬁlter the gene list by (a) ﬁlter-
ing out noise from the data by removing genes with
low intensities or showing little to no variation across
all samples, (b) applying some statistical methods to
extract a list of the most informative genes, which can
beperformedbyANOVAanalysis[29],orsigniﬁcance
analysis of microarrays (SAM) [30]. A more detailed
explanationonstatisticaltechniquescanbefoundelse-
where [31,24]. Key issues on microarray analysis can
alsobefoundathttp://bioinformatics.duke.edu/camda.
The fourth step is to examine the ﬁltered data using
eitherunsupervisedorsupervisedmethods,ormachine
learning algorithms with a cross-validation procedure
[32], which ensures to select the most informative
genes such as artiﬁcial neural network [32] or support
vector machine [33] algorithims. Finally, data mining
can be further performed with databases speciﬁcally
designed for particular purposes (Unigene, Refseq,
Locuslink, Genecards, Gene Ontology, etc.).
5. Proﬁlinghuman prostate cancer g ene
expression
Many new genes involved in PrCa have been
reported since the ﬁrst studies using microarray plat-
forms. A list of novel genes identiﬁed by microarray
analysis with potential importance in prostate cancer
is shown in Table 1. Hepsin, a transmembrane serin
protease, is one of the genes over-expressed in PrCa
compared to benign hyperplasia of normal prostate
[34]. Srikantan et al., found in in vitro assays that
hepsin decreased cell growth and invasion of PC-3
cells [35], which is difﬁcult to reconcile with its up-
regulation in the malignant prostate. However, fur-
ther studies have shown that hepsin over-expression
in vivo causes disorganization of the basement mem-
brane and promotes primary prostate cancer progres-
sion and metastasis to liver, lung, and bone, with no
impact on cell proliferation [36]. Alpha-methylacyl-
CoA racemase (AMACR) is another gene identiﬁed
by microarrays in prostate cancer. AMACR is consis-
tently up-regulated in prostate tumors (approximately
nine-fold) compared to normal tissues [37]. The up-
regulation of this gene, that is involved in peroxisomal
beta oxidation of branched fatty acids, was conﬁrmedA. Calvo et al. / Mutation Research xxx (2005) xxx–xxx 7
Table 1
Selected list of genes discovered by microarray analysis with potential importance in prostate cancer
Gene name Acronim Function Status in PCa Reference
Hepsin Proteolysis Up Dhanasekaran et al. [34]
RabGTPase-activating protein PRC17 Rab GTPase-activating protein Up Pei et al. [43]
Calcium-binding protein S100-P Cell signaling Up Amler et al. [49]
Polycomb group protein
enhancer of zeste homolog 2
EZH2 Actin polymerization and cell signaling Up Varambally et al. [38]
Alpha-methylacyl-CoA racemase AMACR Degradation of branched fatty acids and
C27 steroids
Up Luo et al. [37]
Selenoprotein-P SePP Binding of selenium; protection against
oxidative stress
Down Calvo et al. [60]
Wnt signaling (Wnt 5A) Cell self-renewal Up Glinsky et al. [42]
Elongin-C Unknown Up Porkka et al. [41]
FKBP5 Unknown; androgen-regulated gene N.D. Nelson et al. [44]
ANKH Regulates transportation of Pyrophosphate N.D. Nelson et al. [44]
Prostate A-regulated transcript-1 PART-1 Unknown; androgen-regulated gene Up Lin et al. [45]
Prostate short chain DR1 PSDR-1 Steroid synt.; androgen-regulated gene N.D. Lin et al. [46]
Claudin-8 Paracellular communication Up Ernst et al. [72]
Gro-2 Cell growth regulation Down Ernst et al. [72]
Speciﬁc granule protein-28 SGP28 Unknown Up Ernst et al. [72]
bytissuemicroarraysinalargenumberofsamples[37].
Thefunctionalsigniﬁcanceofthisgeneinprostatecar-
cinogenesis is still unknown.
Microarrayanalysisidentiﬁedgenesup-regulatedin
metastatic PrCa relative to localized PrCa [34]. One of
these genes was the polycomb group protein enhancer
ofzestehomolog2(EZH2),whichisover-expressedin
hormone-refractory, metastatic PrCa [38]. The ectopic
expressionofEZH2inprostatecancercellssilencesthe
expression of a large group of genes. EZH2 may serve
as a marker for risk of lethal progression of PrCa [38].
Ramaswamy et al. [39] described the molecular sig-
natures of metastatic cancers, including prostate. This
familyofgenesconsistedofeightup-regulatedandnine
down-regulated genes. It was the group of genes con-
sidered together, not each of the individual genes, that
representedametastaticsignaturefordifferenttypesof
cancers.Interestingly,manyofthesegeneswererelated
to the non-epithelial compartment of the tumor.
Rhodes et al. [40] have analyzed gene expres-
sion proﬁles in PrCa by microarray meta-analysis of
four published studies. This study generated a cohort
of genes that were commonly dysregulated in PrCa.
Changes included the polyamine and purine biosyn-
thesis pathways. Ampliﬁcation of elongin-C was iden-
tiﬁed as a gene ampliﬁed in prostate cancer cell lines
comparedtonormalprostate[41].Thisgene,locatedin
the region of chromosome 8q, was found to be ampli-
ﬁed in 23% of hormone-refractory carcinomas, but not
in untreated prostate carcinomas [41].
Gene expression proﬁling combined with stratiﬁ-
cation algorithms identiﬁed signature distinguishing
subgroups of PrCa patients with different outcomes
after therapy [42]. This approach allowed the authors
to deﬁne molecular signatures that can serve as prog-
nostic tests at the time of diagnosis. This method
allowsthepatientstobeclassiﬁedintopoor-andgood-
prognosis subgroups with a different disease-free sur-
vival after therapy. These data suggest the presence
of two genetically deﬁned subtypes of tumors lead-
ing to a strongly malignant behavior in one group
(poor-prognostic group) or a non-aggressive behavior
in the other. Activation of Wnt signaling pathways and
decreased expression of FKL6 (COPEB) seem to be
critical genes deﬁning the poor-outcome group [42].
Novel androgen-responsive genes have been identi-
ﬁed by cDNA microarrays in the androgen-dependent
cell line LNCaP [44]. LNCaP cells treated with the
synthetic androgen R1881 at nine different time points
(from 0 to 48h) produced gene expression changes in
146genes(three-foldchange)outof20,000transcripts.
Thesegeneswereinvolvedinmetabolism(suchasfatty
acid synthase and acetyl-CoA-carboxylase), trafﬁck-
ing (such as FKBP-5 and ANKH), cell proliferation8 A. Calvo et al. / Mutation Research xxx (2005) xxx–xxx
and differentiation (such as the maf oncogene, id2, or
cdk8).Anotherstudyidentiﬁedtheandrogen-regulated
genePART-1(prostateandogen-regulatedtranscript-1)
in LNCaP cells [45]. Northern blot analysis demon-
strated that PART-1 is highly expressed in the prostate
relative to other tissues [45]. PSDR-1 was identiﬁed as
another androgen-regulated gene with high expression
in normal and neoplastic prostate. This gene maps in
chromosome 14q23-24.3 and it is involved in steroid
synthesis [46].
Fewpharmacogenomicanalysesofgeneexpression
have been done using microarrays in prostate tumor
cells. Genistein, the major isoﬂavone of soybeans,
inhibits carcinogenesis in vivo and in vitro through
the induction of apoptosis, via down-regulation of
nuclear factor B (NF-B) and akt signaling path-
ways [47]. Treatment of PC-3 with genistein leads to
changes in gene expression proﬁles of genes involved
in many pathways, including cell cycle, transcrip-
tionalregulation,metabolism,angiogenesisandmetas-
tasis. For instance, genistein down-regulated uPA,
MMP-9, VEGF, and TGF-beta. The effect of selenium
(an antioxidant and chemopreventive agent) on PC-3
cells has been evaluated using Affymetrix oligonu-
cleotide arrays [48]. Treatment with selenium pro-
duced changes in gene expression related to cell cycle,
invasion, DNA repair and TGF-beta signaling. Genes
such as GADD153, CHK2, p21(WAF-1), and cyclin A
have been proposed to be key regulators of selenium-
mediated growth inhibition.
Microarrayshavealsobeenusedtoidentifychanges
in copy number of genes or chromosomal regions
throughthemethodofcomparativegenomichybridiza-
tionarray.Astudyusingmicroarrayscontaining31,104
cDNAswasusedtosurveyforDNAampliﬁcationin22
primary prostate tumors [43]. The novel gene, PRC17,
wasfoundtobeampliﬁedinprostatetumors.Thisgene,
located in chromosome 17, is a GTPase-acivated pro-
tein that interacts with Rab-5 and stimulates its GTP
hydrolysis. PRC17 has oncogenic activity in vitro and
in vivo and its over-expression is related to the acqui-
sition of metastatic phenotype [43].
6. Proﬁlingprostate cancer in animal models
Several animal models have been developed to
mimic human prostate carcinoma. These animals have
been characterized mostly by histopathology and little
isknowninmostcasesaboutmolecularpatternsofgene
expression. Although these animals are being used as
preclinical models for therapies, gene expression pro-
ﬁleswillhelpdeterminewhetherthesemodelsaretruly
representativeofthemolecularchangesassociatedwith
the human disease. Validation of gene expression will
show which tumor-pathways are activated in each par-
ticular model and which targets of therapies may be
most appropriate to test in that model. Our lab is cur-
rentlyproﬁlinggeneexpressioninprostatetumorsfrom
transgenic and chemically-induced models. The com-
parison of gene expression proﬁles between animal
models and humans is, however, challenging. One dif-
ﬁculty is that human and mouse or rat arrays do not
often contain a high number of genes in common.
Additionally,nocommonreferenceexistswhichwould
allow direct statistical comparisons between human
and rodent cDNA array data. The current published
informationfromcDNAmicroarraystudiesofprostate
cancer in animals models is summarized below. How-
ever, approaches using single-channel arrays are prov-
ing useful for inter-species comparison of array data
(Michalowska et al., manuscript in preparation).
6.1. Xenograft models
Using cDNA microarray technology, the effect of
androgens on gene expression was investigated in
CWR22 cells xenotransplanted into mice [49]. Andro-
gen deprivation initially causes regression of these
tumors that often become androgen independent after
3–12 months. Androgen deprivation of CWR22 cells
resulted in the decreased expression of 122 genes and
induction of 38 genes, out of 9704 genes contained on
the array. Of the 122 repressed genes, 51% were anno-
tatedandmostofthemwererelatedtocellcycle(cdc2,
cyclin B1, cyclin D2, - and -tubulin), protein degra-
dation and cleavage (cathepsin K, ubiquitin-speciﬁc
protease11, peptidase ), metabolism and respiration
(glyceraldehydes-3-phosphate dehydrogenase, lac-
tate dehydrogenase A, -enolase, phosphoglycerate
mutase, NAPDH dehydrogenase), and transcription
and translation factors (TAFII20, TIF2). Most
androgen-dependent genes (34 out of 38) in the
CWR22 tumors were expressed at similar levels in
the androgen-independent CWR22R tumors. Authors
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androgen-independent growth and proliferation is
accompanied by a re-entry into the proliferative
phase of the cell cycle with the need for androgen.
Twenty-eight out of 122 genes repressed by andro-
gen in CWR22 exhibited low levels of expression in
CWR22Rtumorsaswell.However,incellsre-exposed
to androgen, all the 28 repressed genes returned to
normal or even supra-normal levels.
6.2. Hormone and chemically-induced prostate
carcinoma models
Treatment of rats with sex hormones, chemical car-
cinogens, or combinations, can result in the develop-
ment of PrCa. Long-term treatment with testosterone
and estradiol results in cancer developing in the dorso-
lateral lobes by 12 months [50]. Genes such as TRPM-
2, MMP-7 and Id1 (inhibitor of differentiation) have
been associated with hormone induced prostate car-
cinoma [51]. A microarray study demonstrated that
genesassociatedwithcellproliferationandmetabolism
are induced in this cancer model [52,53]. Those genes
included maspin (a tumor suppressor serpin), FRA2
(belonging to the family of oncogens/tumor suppres-
sor genes), proto-oncogenes (erbB2, junD, K-RAS2B,
c-crk,A-RAF,andSTAT-3),cell-cycleproteinandpro-
liferation markers (G1/S-speciﬁc cyclin D1, presenilin
1, PCNA), as well as genes involved in the synthe-
sis, degradation and turnover of proteins. Addition-
ally, genes regulating energy metabolism, and genes
controlling intracellular signaling and communication
were also induced. This pattern of gene induction sug-
gests that PrCa in this model is highly proliferative and
anabolic. Treatment of rats with carcinogens results
in carcinomas of the dorsolateral and ventral lobes
which are mainly microscopic. However, combined
treatments with hormone and chemical agents (for
instance, MNU and testosterone) cause dorsolateral
prostate carcinomas with a 70–90% incidence in the
Lobund-Wistarrat.Typically,ahighfrequency(>70%)
ofaG→Atransitionmutationatthesecondpositionof
codon 12 of the Ki-ras oncogene is found in this model
[54]. Gene proﬁles of tumors in carcinogen-induced
models is currently being performed in our lab.
The rat castration model has been widely used to
study androgen-regulated genes. Understanding how
androgens regulate gene expression in the prostate
is critical for discovering molecular mechanisms
involved in the transition from androgen-dependent to
androgen-independent prostate cancer. We have per-
formed microarray analysis to proﬁle prostate gene
expression in castrated and castrated plus androgen-
replacedrats,comparedtocontrolrats[55].Ourresults
showed that castration induced the expression of clus-
ters of immune-related genes (including genes IL-
15 and IL-18). The phosphatase and tensin homolog
deleted on chromosome 10 (PTEN) was induced after
castration, which suggests that this gene may be a key
mediator of ventral prostate apoptosis in the absence
of androgens.
6.3. Transgenic models
TheC3(1)/SV40-Tantigenoncomousewastheﬁrst
transgenic model developed which produces cancer of
both the dorsolateral and ventral lobes of the prostate
[56]. Early lesions consist of low grade-PIN (LG-
PIN), which progress to high grade-PIN (HG-PIN),
and then to invasive carcinoma [57,58]. Ha-ras muta-
tions have been reported to occur early in this model
[59]. We have reported gene expression proﬁles in
cell lines isolated from different stages of tumor pro-
gression of the C3(1)/Tag model. Cell lines derived
from LG- and HG-PIN, invasive carcinoma and a lung
metastasis exhibited increasing rates of cell growth,
tumorigenicity, invasiveness, and angiogenesis. cDNA
microarray analysis using an array with 8700 features
was used to compare gene expression patterns of these
cell lines and to correlate these patterns with aggres-
sive malignant behavior [60]. The expression of par-
ticular genes progressively increased from low-grade
PIN to invasive carcinoma. P-cadherin, CEACAM-1,
L1-CAM, adhesion lymphocyte-6 metastasis associ-
ated gene (MTA-2) and S100A8 showed progressive
increasesingeneexpression,associatedwiththecancer
stage from which the cell lines were derived. However,
genes such as TIMP-3, transglutaminase-2, E-, and N-
cadherin, and adducin-3 were progressively repressed.
Some of these gene expression patterns are coincident
with those described for human prostate cancer.
Our analysis also led to the identiﬁcation of novel
genes associated with prostate cancer development.
Examples include the L1-CAM, MTA-2, rab-25, trop-
2,andselenoprotein-P(SePP).Wefurtheranalyzedthe
expressionofSePPinhumanandmouseprostatecarci-
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during protein translation, and is thought to inhibit
oxidativestress.Epidemiologicstudieshavesuggested
that increased levels of selenium are associated with
a signiﬁcant decrease in risk of prostate cancer [61].
Quantitative assays using real-time RT-PCR demon-
strated that SePP was down-regulated in a subset of
human prostate tumors and mouse prostate cancer, and
in several PrCa cell lines. Our results suggest that
a decrease in SePP with reduced protection against
oxidative stress may be one factor associated with
prostate carcinogenesis.
Other transgenic models for prostate cancer have
beendeveloped,butmicroarrayanalyseshavenotbeen
reported.TheseincludemodelswhichusetheSV40/T-
antigen as the oncogenic gene, such as TRAMP,
LADY,fetalglobin/SV40,andCryptidin-2/SV40mod-
els.Morerecently,modelsgeneticallyengineeredmice
lacking PTEN or Nkx3.1 have also been developed. A
review on the natural history of tumor development
and features of mouse models for prostate cancer can
be found elsewhere [4,62]. In addition to transgenic
mice, transgenic rats have also been generated which
overexpressSV40T/t-antigensunderthecontrolofthe
probasin promoter that show atypical epithelial cell
proliferationintheprostateat4weeksofageand100%
incidence of invasive adenocarcinoma at 15 weeks of
age.Inthismodel,tumordevelopmentisstrictlyandro-
gendependent[63].Itwasreportedthataftercastration,
expressionofcaspase3,caspase6,BAX,blc-x,TRPM-
2 and MMP-7 was increased. cDNA arrays with 1200
features showed increased expression of genes such
as MMP-7, trasducin -1, microsomal glutathione S-
transferase, coﬁlin, Na+/K+ ATPase -1 subunit and
TRPM-2, and repression of serotonin receptor 5B,
copper-zinc-containingsuperoxidedismutase1,potas-
sium channel Kir6.2 and gluthatione S-transferase Yb
subunit.InductionofgenesrelatedtoapoptosisorECM
degradationsuchasTRPM-2andMMPwerealsoiden-
tiﬁed [63].
7. Tissue microdisection and gene expression
proﬁling
Prostate cancer is a heterogeneous disease. Glands
from a patient with PrCa can present different types of
lesions, including LG- and HG-PIN, carcinoma in situ,
and invasive carcinoma [1]. Most current microarray
work done so far has utilized bulk tissue that con-
tainsepithelial,stromal,endothelial,andinﬂammatory
cells. This approach has the advantage of getting high
amountsofmRNAthatcanbereadilyanalyzed,buthas
the disadvantage of including a heterogeneous popula-
tion of cells. The laser capture microdissection (LCM)
techniqueisabletoisolateparticulartypesofcellsfrom
whichmRNAorDNAcanbeisolatedandampliﬁedfor
analysisbymicroarrays.Thistechniqueenablestheuse
of pure cell populations and, therefore, the analysis of
gene expression patterns for particular cell types. The
disadvantage of laser capture microdissection is that it
is labor intensive, and that certain biases may be intro-
duced by the ampliﬁcation process.
To isolate individual cells or tissue types, microdis-
section using laser capture was developed at the NCI
and initially described by Liotta’s group [64].N e w
laser-based tools are able to isolate individual prostate
cells and successfully isolate RNA and DNA from
those tissues. The NCI developed the ﬁrst device that
was commercially distributed by Arcturus Engineer-
ing, but many other LCM machines are now com-
mercially available. An important technical issue for
microarray analysis from LCM-isolated tissue is sam-
ple processing. Although cell morphology of parafﬁn-
embedded sections is better preserved than that of
frozensections,RNAintegrityiscompromised.Preser-
vation protocols for laser-captured tissues have been
published for a variety of molecular analyses, includ-
ing RT-PCR [65], cDNA microarrays [66], ﬂuorescent
in situ hybridization and ﬂow cytometry [67], one- and
two-dimensional PAGE [68], and chemiluminescent
immunoassays [69].
Broad application of cDNA microarrays is limited
by the amount of RNA that can be extracted from
the microdissected samples. To enable the use of
microarray technology in instances where the RNA
amount is low, techniques such as linear ampliﬁcation
allow gene expression proﬁles to be monitored [70].
Limited data is available regarding the reproducibility
andmaintenanceoforiginaltranscriptratios.Although
ampliﬁcation methods introduce slight changes in the
transcript ratios, as compared to standard labeling,
they are highly reproducible. Ampliﬁcation systems
currently in use are based on T7 RNA polymerase
methods [70]. Wang et al. [71] demonstrated the
ﬁdelity and linearity of ampliﬁcation methods for
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Gene expression analysis comparing total tissue
with microdissected prostate tissues has been reported
[72]. In this study, two sets of experiments were done.
In the ﬁrst one, bulk tissue from tumor tissue was com-
pared by oligonucleotide arrays with normal adjacent
tissue. Sixty-three genes were found to be increased
in tumors and 153 genes were decreased [72].I nt h e
second set of experiments, pooled epithelial and stro-
mal cells from normal and cancerous tissues were
isolated by LCM and analyzed by microarrays. When
two different pools of epithelial cells were compared
by oligonucleotide microarrays the correlation coef-
ﬁcient was r=0.95, thus showing the reproducibility
of the method. Cancerous epithelia showed the major-
ity of up-regulated genes. A list of tumor epithelial-
speciﬁc genes is listed in their study. Some of the
highly up-regulated genes include claudin-8, SGP28,
and stromelysin 2; highly down-regulated genes
include keratin-5, keratin-7, and chemokine receptor-2
[72].
8. Tissue microarrays
Potential biomarkers identiﬁed by cDNA microar-
rayshavetobefurthervalidatedeitherbyaquantitative
measurementofRNAlevels(northernblot,RT-PCR,or
in situ hybridization) or protein levels (immunohisto-
chemistryorwesternblot).Tissuemicroarraysprovide
aconvenientplatformforperformingahighthroughput
analysis of either RNA (in situ hybridization) or pro-
tein(immunohistochemistry)expression.Tissuearrays
are slides containing hundreds of small tissue sections
from different tissue samples. These arrays may con-
taindisc-shapedtissuesections(approximately0.5mm
in diameter) from many different patients. An impor-
tant advantage of this technique is that all the samples
are evaluated under the same technical conditions with
multiple stages of prostate tumor progression analyzed
in one experiment. Tissue microarrays have already
producedvaluableinformationregardingPrCa,includ-
ing the re-evaluation of the expression of traditional
markers.
Immunohistochemicalstainingquantitatedbycom-
puterizedimageanalysisoftissuemicroarraysfoundan
inverse correlation between Skp-2 protein (a positive
regulator of G1-S transition) and the cyclin dependent
kinase inhibitor p27Kip and PTEN. Arrayed samples
included 622 radical prostatectomies, 74 PIN, and 4
normalprostates.Spk2expressioncorrelatedpositively
withpreoperativePSAlevelsandGleasonscore.Tissue
arrays have also been used to evaluate the expres-
sion of annexins in PrCa. Annexins are a family of
proteins whose expression is altered during prostate
carcinogenesis. Previous in vitro studies showed that
the expression of annexin II and annexin VII is lost in
prostatetumorsandPrCacelllines.Tissuemicroarrays
have revealed a decrease in annexin I, II, IV, VII and
XI in hormone refractory PrCa compared to localized
PrCa[73].High-densitytissuemicroaraysalsodemon-
strated that AMACR protein was broadly expressed in
PrCassamples[74].AMACRproteinwassigniﬁcantly
increased in localized hormone-na¨ ıve PrCa as com-
paredtobenignprostatelesions.AMACRwasreduced
in patients who received neoadjuvant hormone treat-
ment [74].
9. Microarray analysis for studies of cancer
epigenetic changes
Epigenetic changes are deﬁned as alterations in
gene function that are not due to changes in DNA
sequence. Compared with their normal counterparts,
cancercellsexhibitsigniﬁcantchangesinDNAmethy-
lation patterns. Abnormal cytosine methylation is a
widespread phenomenon in cancer, which can result in
transcriptional inactivation of tumor suppressor genes,
and genes involved in cell regulation and DNA repair.
Hypermethylation has been reported to be responsible
for silencing of more than 100 genes in different types
of cancers. The expression of many genes have been
found in prostate cancer as a result of aberrant methy-
lation, including GSTP1, E-cadherin, AR, p16, PTEN,
and CD44 [75]. GSTP1 is of particular importance
since close to 100% of prostate tumors lose expression
of this caretaker gene, which protects cells against
oxidative DNA damage [76]. Aberrant methylation of
genes seems to be a critical step in prostate tumor pro-
gression.Avarietyofmethodshavebeenusedtoevalu-
atethemethylationstatusofparticulargenes.Southern
blot, restriction enzyme PCR, bisulﬁte genomic
sequencing, methylation-speciﬁc PCR, methylation-
sensitivesinglenucleotideprimerextension,restriction
landmark genomic scanning (RLGS), representational
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domaincolumnshavebeenwidelyused[77].However,
these methods only examine methylation of individual
genes and are labor intense.
Novel high throughput techniques such as microar-
ray analysis in combination with classical meth-
ods are currently being used to evaluate a large
number of methylated genes in a single experi-
ment. Methylation-speciﬁc oligonucleotide microar-
rays (MSO) uses bisulﬁte-modiﬁed DNA as targets
that are hybridized with arrayed oligonucleotides that
can discriminate between methylated and unmethy-
latedcytosines[78].Thismethodallowsarapidscreen-
ing of multiple CpG sites in many gene promoters and
hasbeenvalidatedforestrogenreceptoralphainbreast
carcinoma [78]. A similar method has been used to
analyzethemethylationstatusofgenesinprostatecan-
cer. Between 32 and 47% of these genes were methy-
lated in PrCa cell lines compared to control samples.
This high throughput screening shows the potential of
this new methodology in the diagnosis of PrCa. The
useofmethylation-speciﬁcendonucleasesincombina-
tion with microarray technology have also been used
for the analysis of methylated genes in breast can-
cer [79]. For this technique, called methylation target
array (MTA), DNA fragments containing CpG islands
are ﬁrst isolated, ligated, digested with methylation-
sensitive endonucleases, and PCR-ampliﬁed. DNA
fragments containing methylated recognition sites are
protected from the digestion and, therefore, ampli-
ﬁed by PCR, while unmethylated or partially methy-
lated DNA is cut and not ampliﬁed. In this study,
468 MTA amplicons, with represent the whole set of
methylated CpG islands of breast tissues were arrayed
on nylon membranes for hybridization [79]. Different
PCR probes were generated, labeled with 32P-dCTP
and hybridized. Using this method, a high frequency
of hypermethylation (higher than 50%) was found in
breast tumors for GPC3 and RASSF1A genes [79].
Another approach for ﬁnding novel cancer-methylated
genes is the treatment of cell lines with demethy-
lating agents (such as 5-aza-2-deoxycytidine) or his-
tone acetylating drugs (such as trichostatin), which re-
expresscancersilencedgenes.Patternsofgeneexpres-
sion of treated and untreated cells can be then com-
pared by microarray analysis, thus establishing lists
of genes which are likely methylated in tumors [80].
This methodology has been applied to bladder cancer
cellsandﬁbroblasts,showingthathypermethylationof
numerous genes occur in tumorigenic cells compared
to non-tumorigenic cells [80].
10. Concludingremarks
Expression studies using microarray analyses are
currently identifying a large number of novel genes
that may have potential roles in prostate carcinogen-
esis. Determining the functional signiﬁcance of such
genes remains a tremendous challenge. However, the
generation of lists of genes which are reproducible
among many labs and that can distinguish biologic dif-
ferencesbetweenthenaturalhistoryofprostatetumors
or their response to therapies will be a major advance
in the ﬁeld. Although proﬁling of mRNA expression
provides important information of gene activity on
a transcriptional level, the development of new pro-
teomictechnologieswillallowforanevenmoreprecise
global insight into derangements of cellular activities
and functions.
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